Danaher Lifts Full-Year EPS Outlook After Q3 Beat
DHR sits 43% above its 52-week low of $160.93.
Summary
Danaher beat on both lines for Q3: adjusted EPS of $2.11 versus $1.92 consensus, and revenue up 8.5% to $6.6 billion, slightly ahead of the $6.559 billion expected. Core growth of 3% landed at the top of the 2%-3% guide, and excluding respiratory testing it was 5.5%, which is the number management is pointing to as evidence demand is improving. The bigger item is guidance: full-year adjusted EPS was raised to $8.57-$8.62 from $8.45-$8.60, above the $8.51 consensus, and the CFO framed 4%-5% core growth ex-respiratory as the starting point for 2027. Adjusted operating margin near 30% shows the incremental revenue is dropping through. Shares are up about 3% at $231, near the 52-week high of $242.80, so the move is real but not a re-rating. Note the Q3 EPS included a $263 million tax benefit, and debt sits at $26.5 billion after the Masimo deal, so watch the leverage and the respiratory headwind into Q4.
At the time of this announcement, DHR was trading at $230.83 on NYSE in the Life Sciences sector, with a market capitalization of approximately $162.3B. The 52-week trading range was $160.93 to $242.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.